BridgeBio Reports Positive Phase 3 Results for Infigratinib in Achondroplasia
Feb 12, 2026
BridgeBio Pharma announced positive Phase 3 topline results for infigratinib in children with achondroplasia, meeting primary and key secondary endpoints. The company plans regulatory submissions in the U.S. and Europe in the second half of 2026.